News
Release
Proteomics
Research Article Cites HemogloBind™
in Profiling Lung Injury
MONMOUTH
JUNCTION, NJ, September
7, 2016 -- Biotech Support Group reports on a recent research article
describing the describing
the simplicity and efficiency of their hemoglobin depletion
technology for improving the proteomic information obtained from
bronchoalveolar lavage fluid (BALF). The citation is:
Maneesh
Bhargava,
Kevin
J. Viken,
Sanjoy
Dey,
Michael
S. Steinbach,
Baolin
Wu,
Pratik
D. Jagtap,
LeeAnn
Higgins, Angela
Panoskaltsis-Mortari,
Daniel
J. Weisdorf,
Vipin
Kumar,
Mukta
Arora,
Peter
B. Bitterman,
David
H. Ingbar,
Chris
H. Wendt.
Proteome
Profiling in Lung Injury after Hematopoietic Stem Cell
Transplantation. Biol
Blood Marrow Transplant 22 (2016) 1383-1390.http://www.bbmt.org/article/S1083-8791(16)30060-X/fulltext
The
authors consider pulmonary complications due to infection and
idiopathic pneumonia syndrome (IPS) in hematopoietic stem cell
transplant (HSCT) recipients. For this, a proteomic characterization
of global bronchoalveolar lavage fluid (BALF) was studied to identify
proteins and pathways that differentiate IPS from infectious lung
injury after HSCT. Because the BALF samples appeared tinged with
blood, the authors tested HemogloBind™ to determine whether the
removal of hemoglobin (in addition to high-abundance proteins) would
improve the depth of coverage. The article states “Hemoglobin
removal improved protein identification to 845 proteins at 1% global
FDR compared with 496 proteins with high-abundance protein depletion
alone”. The authors conclude that the protein expression
differences provide insights into mechanisms activated in lung injury
and suggest potential therapeutic targets to augment lung repair.
“I
am very pleased that this article demonstrates the proteomic utility
of removing hemoglobin from tissue samples containing small amounts
of blood. It is very impressive that the use of HemogloBind™
improved the depth of coverage by almost 2-fold” states Swapan Roy,
Ph.D., President and Founder of Biotech Support Group.
For
more information on HemogloBind™,
visit:
http://www.biotechsupportgroup.com/HemogloBind-Hemoglobin-Depletion-From-Hemolyzed-p/h0145.htm
About
Biotech Support Group LLC
Converging
with cultural and technological disruptions forthcoming in
healthcare, Biotech Support Group develops methods for cost effective
and efficient sample prep essential for these expanding markets.
Following a tiered business strategy, the company continues its
growth in the consumable research products area supporting the
rapidly expanding installation of LC-MS instrument and computational
infrastructure. For this market, key products include: AlbuVoid™
and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid
adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,
and NuGel™ for functional proteomics. From these innovations, the
company has acquired knowledgebase and biomarker intellectual
property assets that support discoveries of protein markers from
blood, with special emphasis on early detection and personalized
medical decisions for cancer patients. For more information,
go to http://www.biotechsupportgroup.com
Contact:
Dr.
Swapan Roy & Matthew Kuruc
Biotech
Support Group LLC
1
Deer Park Drive, Suite M
Monmouth
Junction NJ 08852
732-274-2866
Worldwide
800-935-0628
North
America
sales@biotechsupportgroup.com
http://www.biotechsupportgroup.com